Table of Contents

2019-2024 Global Alzheimer's Disease Drug Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Alzheimer's Disease Drug Consumption 2014-2024
  • 2.1.2 Alzheimer's Disease Drug Consumption CAGR by Region
• 2.2 Alzheimer's Disease Drug Segment by Type
  • 2.2.1 Donepezil
  • 2.2.2 Memantine
  • 2.2.3 Rivastigmine
• 2.3 Alzheimer's Disease Drug Consumption by Type
  • 2.3.1 Global Alzheimer's Disease Drug Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Alzheimer's Disease Drug Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Alzheimer's Disease Drug Sale Price by Type (2014-2019)
• 2.4 Alzheimer's Disease Drug Segment by Application
  • 2.4.1 Early to Moderate Stages
  • 2.4.2 Moderate to Severe Stages
• 2.5 Alzheimer's Disease Drug Consumption by Application
  • 2.5.1 Global Alzheimer's Disease Drug Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Alzheimer's Disease Drug Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Alzheimer's Disease Drug Sale Price by Application (2014-2019)

3 Global Alzheimer's Disease Drug by Players

• 3.1 Global Alzheimer's Disease Drug Sales Market Share by Players
  • 3.1.1 Global Alzheimer's Disease Drug Sales by Players (2017-2019)
  • 3.1.2 Global Alzheimer's Disease Drug Sales Market Share by Players (2017-2019)
• 3.2 Global Alzheimer's Disease Drug Revenue Market Share by Players
  • 3.2.1 Global Alzheimer's Disease Drug Revenue by Players (2017-2019)
  • 3.2.2 Global Alzheimer's Disease Drug Revenue Market Share by Players (2017-2019)
• 3.3 Global Alzheimer's Disease Drug Sale Price by Players
• 3.4 Global Alzheimer's Disease Drug Manufacturing Base Distribution, Sales Area, Product Types by Players
  • 3.4.1 Global Alzheimer's Disease Drug Manufacturing Base Distribution and Sales Area by Players
  • 3.4.2 Players Alzheimer's Disease Drug Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Alzheimer's Disease Drug by Regions

• 4.1 Alzheimer's Disease Drug by Regions
  • 4.1.1 Global Alzheimer's Disease Drug Consumption by Regions
  • 4.1.2 Global Alzheimer's Disease Drug Value by Regions
• 4.2 Americas Alzheimer's Disease Drug Consumption Growth
• 4.3 APAC Alzheimer's Disease Drug Consumption Growth
• 4.4 Europe Alzheimer's Disease Drug Consumption Growth
• 4.5 Middle East & Africa Alzheimer's Disease Drug Consumption Growth

5 Americas

• 5.1 Americas Alzheimer's Disease Drug Consumption by Countries
  • 5.1.1 Americas Alzheimer's Disease Drug Consumption by Countries (2014-2019)
  • 5.1.2 Americas Alzheimer's Disease Drug Value by Countries (2014-2019)
• 5.2 Americas Alzheimer's Disease Drug Consumption by Type
• 5.3 Americas Alzheimer's Disease Drug Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Alzheimer's Disease Drug Consumption by Countries
  • 6.1.1 APAC Alzheimer's Disease Drug Consumption by Countries (2014-2019)
  • 6.1.2 APAC Alzheimer's Disease Drug Value by Countries (2014-2019)
• 6.2 APAC Alzheimer's Disease Drug Consumption by Type
• 6.3 APAC Alzheimer's Disease Drug Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Alzheimer's Disease Drug by Countries
  • 7.1.1 Europe Alzheimer's Disease Drug Consumption by Countries (2014-2019)
  • 7.1.2 Europe Alzheimer's Disease Drug Value by Countries (2014-2019)
• 7.2 Europe Alzheimer's Disease Drug Consumption by Type
• 7.3 Europe Alzheimer's Disease Drug Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Alzheimer's Disease Drug by Countries
  • 8.1.1 Middle East & Africa Alzheimer's Disease Drug Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Alzheimer's Disease Drug Value by Countries (2014-2019)
• 8.2 Middle East & Africa Alzheimer's Disease Drug Consumption by Type
• 8.3 Middle East & Africa Alzheimer's Disease Drug Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 Alzheimer's Disease Drug Distributors
• 10.3 Alzheimer's Disease Drug Customer

11 Global Alzheimer's Disease Drug Market Forecast

• 11.1 Global Alzheimer's Disease Drug Consumption Forecast (2019-2024)
• 11.2 Global Alzheimer's Disease Drug Forecast by Regions
  • 11.2.1 Global Alzheimer's Disease Drug Forecast by Regions (2019-2024)
  • 11.2.2 Global Alzheimer's Disease Drug Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Alzheimer's Disease Drug Forecast by Type
• 11.8 Global Alzheimer's Disease Drug Forecast by Application

12 Key Players Analysis

• 12.1 Allergan
  • 12.1.1 Company Details
  • 12.1.2 Alzheimer's Disease Drug Product Offered
  • 12.1.3 Allergan Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 Allergan News
• 12.2 Eisai
  • 12.2.1 Company Details
  • 12.2.2 Alzheimer's Disease Drug Product Offered
  • 12.2.3 Eisai Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 Eisai News
• 12.3 Novartis
  • 12.3.1 Company Details
  • 12.3.2 Alzheimer's Disease Drug Product Offered
  • 12.3.3 Novartis Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Novartis News
• 12.4 Daiichi Sankyo
  • 12.4.1 Company Details
  • 12.4.2 Alzheimer's Disease Drug Product Offered
  • 12.4.3 Daiichi Sankyo Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 Daiichi Sankyo News
• 12.5 Merz Pharma
  • 12.5.1 Company Details
  • 12.5.2 Alzheimer's Disease Drug Product Offered
  • 12.5.3 Merz Pharma Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 Merz Pharma News
• 12.6 Pfizer
  • 12.6.1 Company Details
  • 12.6.2 Alzheimer's Disease Drug Product Offered
  • 12.6.3 Pfizer Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.6.4 Main Business Overview
  • 12.6.5 Pfizer News
• 12.7 Johnson & Johnson
  • 12.7.1 Company Details
  • 12.7.2 Alzheimer's Disease Drug Product Offered
  • 12.7.3 Johnson & Johnson Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.7.4 Main Business Overview
  • 12.7.5 Johnson & Johnson News
• 12.8 Lundbeck
  • 12.8.1 Company Details
  • 12.8.2 Alzheimer's Disease Drug Product Offered
  • 12.8.3 Lundbeck Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.8.4 Main Business Overview
  • 12.8.5 Lundbeck News

13 Research Findings and Conclusion

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
In the last several years, global market of alzheimer’s disease drug change huge.
The classification of alzheimer’s disease drug includes Memantine, Donepezil, Rivastigmine and Others, and the proportion of Memantine in 2016 is about 49.28%. The market for Donepezil, is decreast quickly in past five years.
Alzheimer’s disease drug are widely used for Early to Moderate, Moderate to Severe stage treatment. The most proportion of alzheimer’s disease drug used to Moderate to Severe, and the market share in 2016 is 55.82%.

According to this study, over the next five years the Alzheimer's Disease Drug market will register a -11.3% CAGR in terms of revenue, the global market size will reach US$ 1580 million by 2024, from US$ 2870 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Alzheimer's Disease Drug business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Alzheimer's Disease Drug market by product type, application, key manufacturers and key regions and countries.

This study considers the Alzheimer's Disease Drug value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Donepezil
Memantine
Rivastigmine
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Early to Moderate Stages
Moderate to Severe Stages

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Alzheimer's Disease Drug consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Alzheimer's Disease Drug market by identifying its various subsegments.
Focuses on the key global Alzheimer's Disease Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Alzheimer's Disease Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Alzheimer's Disease Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.